IVAX erhält die Zulassung der FDA.......... - 500 Beiträge pro Seite

[hallole]

Generika-Hersteller Ivax (IVX) erhält die Zulassung der amerikanischen Gesundheitsbehörde FDA für doxazosin mesylate, einer generische Version von Pfizer`s Cardura gegen Bluthochdruck

[mitie]

Schaut man sich die Einschätzungen auf http://biz.yahoo.com/n/i/ivx.html an, so kann man davon ausgehen, dass IVX momentan ein klarer Kauf ist.Der seit November anhaltende Abwärtstrend wurde nach oben durchbrochen.
Moderates Wachstum ist zu erwarten, die Gewinnaussicheten liegen bei +20% im Jahre 2001.

Mike

[mitie]

Am vergangegen Dienstag wurden die Zahlen für das 4. Quartal im Jahre 2000 bekanntgegeben:

Tuesday February 6, 8:31 am Eastern Time

Press Release
IVAX Announces Record Fourth Quarter and Year 2000 Earnings
MIAMI--(BUSINESS WIRE)--Feb. 6, 2001--IVAX Corporation (AMEX:IVX - news) reported record financial results for the fourth quarter and year ended December 31, 2000.

Income from continuing operations for the fourth quarter of 2000 was $49.7 million, or $.30 per diluted share, an increase of 66% over fourth quarter 1999`s income from continuing operations of $29.8 million, or $.19 per diluted share. Net revenues for the fourth quarter of 2000 were $242 million, an increase of 27%, compared to net revenues of $191 million in the fourth quarter last year.

For the year ended December 31, 2000, income from continuing operations increased by 101% to 139.8 million, or $.86 per diluted share, compared to $69.5 million, or $.42 per diluted share, for fiscal 1999. Net revenues for 2000 increased by 21% to $793 million from $656 million in the prior year.

``I am extremely pleased to report these record earnings for the fourth quarter and fiscal year 2000,`` said Phillip Frost, M.D., IVAX chairman and chief executive officer. ``We were able to achieve these results, while increasing our research and development spending by 22.4% during 2000.``

Neil Flanzraich, vice-chairman and president of IVAX said, ``IVAX` gross profit margin was 49% of net revenues for the fourth quarter of 2000 compared to 43% in the fourth quarter of 1999. The improvement in gross profit percentage was due in part to IVAX` paclitaxel sales, which reached $35 million in the fourth quarter.`` Mr. Flanzraich added, ``This is IVAX` twelfth consecutive quarter of significant year-over-year earnings growth, and we are confident our strong growth will continue.``



Hört sich doch klasse an!

Mike

[Bomber100]

IVAX bringt nur gute Nachrichten und trotzdem geht das Ding nicht hoch.